Valganciclovir in cytomegalovirus prophylaxis in renal transplant recipients


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. Estimation of efficacy of prophylaxis of cytomegalovirus infection with valganciclovir in renal transplant recipients. Methods. Retrospective study included 349 renal transplant recipients: 17i of them received valganciclovir during 3 - 6 months. Patients, who received tacrolimus, more frequently used tacrolimus, those, who did not -cyclosporine. Median follow-up period duration was > 2 years (25,8 [і2,5; 40,6] months in valganciclovir group, 65.4 [50,6; 97,4] months in control group). Results. Valganciclovir use lead to decrease of frequency of active cytomegalovirus infection during 12 months of follow-up (7,0 % vs 22,6 %, p < 0,001), frequency of replication of all herpes-group viruses (9,2 % vs 32,4 %, p < 0,001); trend to decrease of all pneumonias was also observed (9,7 % vs 16 %, p = 0,ii). 1- and 2-year event-free survival was also higher in valganciclovir group (1-year: 78.4 % vs 65,2 %, P = 0,006; 2-year: 76,6 % VS 63,5 %, P = 0,009). Conclusion. Use of valganciclovir in renal transplant recipients leads to decrease of frequency of active cytomegalovirus infection and increase in event-free survival.

Full Text

Restricted Access

References

  1. Очерки клинической трансплантологии / Под ред. С.В. Готье. М. — Тверь, ООО «Издательство «Триада», 2009. 360 с.
  2. Трансплантация почки / Пер. с англ. под ред. Я.Г. Мойсюка. — М., ГЭОТАР-Медиа, 2013. 848 с.
  3. Harvala H., Stewart C., Muller K. et al. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy // J. Med. Virol. — 2013; 85(5):893-898.
  4. Rubin R.H. The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: The end of the ‘silo hypothesis’ // Curr. Opin. Infect. Dis. — 2007; 20: 399-407.
  5. Egli A., Binggeli S., Bodaghi S. et al. Cytomegalovirus and polyomavirus BK posttransplant // Nephrol. Dial. Transplant. — 2007; 22 (Suppl 8): viii72-viii82.
  6. Toupance O., Bouedjoro-Camus M.C., Carquin J. et al. Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses// Transpl. Int. — 2000; 6: 413—419.
  7. Hjelmesaeth J., Muller F., Jenssen T. et al. Is there a link between cytomegalovirus infection and new-onsetpost transplantation diabetes mellitus? Potential mechanisms of virus induced beta-cell damage // Nephrol. Dial. Transplant. — 2005; 20: 2311—2315.
  8. Courivaud C., Bamoulid J., Chalopin J.M. et al. Cytomegalovirus exposure and cardiovascular disease in kidney transplant recipients // J. Infect. Dis. — 2013; 207(10):1569—1575.
  9. Fellay J., Venetz J.P., Pascual M. et al. Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir // Am. J. Transplant. — 2005; 5 (7):1781—1782.
  10. Valentine V.G., Weill D., Lombard G.A. et al. Ganciclovir for cytomegalovirus: A call for indefinite prophylaxis// Am. J. Transplant. — 2007; 7 (S2): 505.
  11. Boudreault A.A., Xie H., Rakita R.M. et al. Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis // Transpl. Infect. Dis. — 2011; 13(3): 244—249.
  12. Papasotiriou M., Papachristou E., Marangos M. et al. Cytomegalovirus polyradiculopathy of late onset in a young renal transplant recipient // Clin. Nephrol — 2013; 80(1):75—78.
  13. Humar A., Lebranchu Y., Vincenti F. et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients//Am. J. Transplant. — 2010; 10: 1228—1237.
  14. Luan F.L., Stuckey L.J., Park J.M. et al. Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection // J. Am. Soc. Nephrol. — 2009; 20(11): 2449—2458.
  15. Witzke O., Hauser I.A., Bartels M. et al. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial // Transplantation. — 2012; 93(1): 61—68.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies